144 related articles for article (PubMed ID: 36787661)
1. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L; Ardizzone D; Tachibana I; Adra N; Cary C; Hugar L; Sexton WJ; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Cazzaniga W; Nicol D; Gerdtsson A; Tandstad T; Fizazi K; Fankhauser CD;
J Clin Oncol; 2023 Dec; 41(34):5296-5305. PubMed ID: 37656935
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
[TBL] [Abstract][Full Text] [Related]
4. Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors.
Kundu SD; Feldman DR; Carver BS; Gupta A; Bosl GJ; Motzer RJ; Bajorin DF; Sheinfeld J
J Urol; 2015 Feb; 193(2):513-8. PubMed ID: 25150639
[TBL] [Abstract][Full Text] [Related]
5. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
[TBL] [Abstract][Full Text] [Related]
6. Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor.
Nason GJ; Jewett MAS; Bostrom PJ; Goldberg H; Hansen AR; Bedard PL; Sturgeon J; Warde P; Chung P; Anson-Cartwright L; Sweet J; Atenafu EG; O'Malley M; Hamilton RJ
Eur Urol Oncol; 2021 Apr; 4(2):289-296. PubMed ID: 32907779
[TBL] [Abstract][Full Text] [Related]
7. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H
Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325
[TBL] [Abstract][Full Text] [Related]
8. [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].
Paffenholz P; Pfister D; Heidenreich A
Urologe A; 2016 May; 55(5):632-40. PubMed ID: 26820659
[TBL] [Abstract][Full Text] [Related]
9. Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma.
Clevenger JA; Foster RS; Ulbright TM
Mod Pathol; 2009 Oct; 22(10):1361-6. PubMed ID: 19633644
[TBL] [Abstract][Full Text] [Related]
10. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer.
Li R; Duplisea JJ; Petros FG; González GMN; Tu SM; Karam JA; Huynh TT; Ward JF
Eur Urol Oncol; 2021 Aug; 4(4):651-658. PubMed ID: 31412007
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
12. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of patient outcomes with subcentimeter disease after chemotherapy for metastatic non-seminomatous germ cell tumor.
Ravi P; Gray KP; O'Donnell EK; Sweeney CJ
Ann Oncol; 2014 Feb; 25(2):331-8. PubMed ID: 24276027
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
[TBL] [Abstract][Full Text] [Related]
15. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
[TBL] [Abstract][Full Text] [Related]
16. Retroperitoneal lymph node dissection after chemotherapy for germ cell tumours: is a full bilateral template always necessary?
Steiner H; Peschel R; Bartsch G
BJU Int; 2008 Aug; 102(3):310-4. PubMed ID: 18325053
[TBL] [Abstract][Full Text] [Related]
17. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
18. The impact of bleomycin on retroperitoneal histology at post-chemotherapy retroperitoneal lymph node dissection of good risk germ cell tumors.
Cary KC; Pedrosa JA; Kaimakliotis HZ; Masterson TA; Einhorn LH; Foster RS
J Urol; 2015 Feb; 193(2):507-12. PubMed ID: 25254937
[TBL] [Abstract][Full Text] [Related]
19. Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.
Kamel MH; Littlejohn N; Cox M; Eltahawy EA; Davis R
J Endourol; 2016 May; 30(5):510-9. PubMed ID: 26669219
[TBL] [Abstract][Full Text] [Related]
20. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]